Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics Q3 net loss widens to $50.4 million; cash $388.9 million

Negative Impact 3 of 5 earnings Written later

Allogene Therapeutics reported a third-quarter 2026 net loss of $50.4 million, or $0.15 per share, up from a net loss of $41.4 million, or $0.19 per share, a year earlier. The company reported no collaboration revenue and said its cash, cash equivalents and investments of $388.9 million fund its operations into 2029, while its 2026 GAAP operating expense outlook is about $225 million.

Key points

  • Q3 2026 net loss was $50.4 million, or $0.15 per share, versus $41.4 million, or $0.19 per share, in Q3 2025
  • Research and development expenses were $41.9 million and general and administrative expenses were $12.9 million in Q3 2026
  • Cash, cash equivalents and investments were $388.9 million as of September 30, 2026; cash runway projected into 2029
  • 2026 guidance: operating expense about $165 million; GAAP operating expenses about $225 million, including about $35 million of stock-based compensation

The filing

CompanyAllogene Therapeutics, Inc. (ALLO)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:09 PM ET
Accession number0001628280-26-071040

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.